Physician profile
Phyllis J Byrd
NPI 1831206739
$1,434.38
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $59.96 · 2021: $481 · 2022: $481 · 2023: $21.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $21.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $21.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $291.15 | 2019-2022 | |
| Abbvie INC. | $151.36 | 2019-2023 | Qulipta |
| Therapeuticsmd, INC. | $125.00 | 2019 | |
| Amgen INC. | $87.59 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $69.63 | 2022 | |
| Amarin Pharma, INC. | $56.96 | 2020-2021 | |
| Lilly USA, LLC | $49.25 | 2020-2021 | |
| Genentech USA, INC. | $49.11 | 2019-2021 | |
| Medtronic, INC. | $45.19 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $44.35 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $43.80 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.54 | 2022 | |
| Merck Sharp & Dohme LLC | $39.27 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $38.18 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.48 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $34.94 | 2022 | |
| Sanofi-Aventis U.S. LLC | $31.82 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.18 | 2021-2022 | |
| Glaxosmithkline, LLC. | $24.88 | 2021 | |
| Neos Therapeutics, LP | $24.73 | 2022 | |
| Eisai INC. | $19.98 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.68 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.68 | 2019 | |
| Astellas Pharma US INC | $15.98 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.16 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.49 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.10 | 2022 | |
| Pfizer INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.